Stoke Therapeutics Inc expected to post a loss of 62  cents a share - Earnings Preview

Stoke Therapeutics

04/03/2022 16:57

* Stoke Therapeutics Inc  STOK.OQ   STOK.O  is expected
to show no
change in quarterly revenue when it reports  results on March 7
(estimated). 
    * ​Refinitiv's mean analyst estimate for Stoke Therapeutics
Inc is
for a loss of 62 cents per share. For the same quarter last
year, the company reported a loss of 42 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Stoke
Therapeutics Inc is $61.5​, about 68.8% above​ its last closing
price of $19.20. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.61       -0.59      -0.61     Missed  -3.8
 Jun. 30 2021  -0.45       -0.47      -0.60     Missed  -27.7
 Mar. 31 2021  -0.44       -0.44      -0.46     Missed  -4.5​
 Dec. 31 2020  -0.41       -0.42      -0.42     Met     -0.2
 ​​Sep.        -0.44       -0.41      -0.41     Met     1
 30 2020                                                
 Jun. 30 2020  -0.36       -0.35      -0.39     Missed  -10​
 Mar. 31 2020  -0.36       -0.36      -0.34     Beat    4.5
 Dec. 31 2019  -0.31       -0.31      -0.09     Beat    71.2
 This summary was machine generated March 4 at 16:57 GMT.  All
figures in US dollars  unless otherwise stated